4/23/2013

GlaxoSmithKline and Avalon Ventures, a venture capital firm, will fund up to 10 early-stage drug developers over the next three years. GSK will provide technical support and up to $465 million in initial funding and milestone payments, and will have first rights to buy each startup.

Related Summaries